|
CA2868121C
(en)
*
|
2012-03-23 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
WO2014031476A1
(en)
|
2012-08-21 |
2014-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
WO2016133829A1
(en)
*
|
2015-02-17 |
2016-08-25 |
Full Spectrum Genetics, Inc. |
Novel sd1 binding compounds and uses thereof
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
CN106467573B
(zh)
|
2015-08-21 |
2021-05-25 |
佧珐药业有限公司 |
抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
|
|
EP4477269A3
(en)
|
2015-09-20 |
2025-03-19 |
The United States of America, as Represented By the Secretary, Department of Health and Human Services |
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
CA3019835A1
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
HRP20251020T1
(hr)
|
2016-05-20 |
2025-10-24 |
Harpoon Therapeutics, Inc. |
Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
KR102530742B1
(ko)
|
2016-05-20 |
2023-05-09 |
하푼 테라퓨틱스, 인크. |
단일 도메인 혈청 알부민 결합 단백질
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
AU2017305170A1
(en)
|
2016-08-02 |
2019-02-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US20190218294A1
(en)
|
2016-09-09 |
2019-07-18 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
CN110177803A
(zh)
|
2016-11-22 |
2019-08-27 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重新编程的组合物和方法
|
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
|
|
KR102275008B1
(ko)
|
2016-11-23 |
2021-07-13 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
EP3559038B1
(en)
|
2016-12-21 |
2022-12-14 |
The United States of America as represented by The Secretary Department of Health and Human Services |
Human monoclonal antibodies specific for flt3 and uses thereof
|
|
AU2018219226B2
(en)
|
2017-02-07 |
2024-12-19 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
AU2018240556B2
(en)
*
|
2017-03-24 |
2025-02-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD33 immunotherapy
|
|
SG10202107880XA
(en)
*
|
2017-05-12 |
2021-09-29 |
Harpoon Therapeutics Inc |
Mesothelin binding proteins
|
|
US10730954B2
(en)
|
2017-05-12 |
2020-08-04 |
Harpoon Therapeutics, Inc. |
MSLN targeting trispecific proteins and methods of use
|
|
WO2018213612A1
(en)
*
|
2017-05-18 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides and proteins
|
|
US11389480B2
(en)
|
2017-05-19 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
|
|
WO2018232020A1
(en)
|
2017-06-13 |
2018-12-20 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
WO2019043026A1
(en)
*
|
2017-08-30 |
2019-03-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTI-MESOTHELIC RADIOMARQUATED SINGLE DOMAIN ANTIBODIES SUITABLE FOR IMAGING AND TREATING CANCERS
|
|
CA3078969A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
KR101966362B1
(ko)
*
|
2017-10-20 |
2019-04-05 |
주식회사 녹십자 |
항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
|
US11802163B2
(en)
|
2017-11-10 |
2023-10-31 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting glypican-3 or mesothelin
|
|
CN111479590A
(zh)
*
|
2017-12-13 |
2020-07-31 |
艾诺奥医药品有限公司 |
靶向间皮素的癌症疫苗及其使用
|
|
CN108129566B
(zh)
*
|
2017-12-31 |
2021-05-11 |
中国科学院武汉病毒研究所 |
靶向间皮素的c-型单域抗体及其制备方法与应用
|
|
WO2019144095A1
(en)
|
2018-01-22 |
2019-07-25 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for car t cells
|
|
AU2019218729B2
(en)
|
2018-02-06 |
2025-12-04 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための配列決定法
|
|
WO2019178546A1
(en)
|
2018-03-16 |
2019-09-19 |
Scipher Medicine Corporation |
Methods and systems for predicting response to anti-tnf therapies
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
CA3102036A1
(en)
*
|
2018-06-18 |
2019-12-26 |
Anwita Biosciences, Inc. |
Cytokine fusion proteins and uses thereof
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
JP7459043B2
(ja)
|
2018-07-12 |
2024-04-01 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
親和性成熟ｃｄ２２特異的モノクローナル抗体およびその使用
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
AU2019301206B2
(en)
|
2018-07-12 |
2025-10-30 |
Invox Pharma Limited |
Antibody molecules that bind CD137 and OX40
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811450D0
(en)
*
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
BR112021000394A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
CA3106544A1
(en)
|
2018-08-08 |
2020-02-13 |
Mitchell Ho |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
|
KR102879284B1
(ko)
*
|
2018-08-29 |
2025-10-31 |
난징 레전드 바이오테크 씨오., 엘티디. |
항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
|
|
SG11202101811VA
(en)
|
2018-08-30 |
2021-03-30 |
Tcr2 Therapeutics Inc |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN119306844A
(zh)
|
2018-09-25 |
2025-01-14 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
CN109406765B
(zh)
*
|
2018-10-23 |
2022-02-01 |
大连博格林生物科技有限公司 |
细胞增殖与毒性检测试剂盒
|
|
AU2020206308B2
(en)
*
|
2019-01-08 |
2026-02-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
WO2020154150A1
(en)
|
2019-01-22 |
2020-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
|
MY204320A
(en)
|
2019-03-29 |
2024-08-22 |
Mogam Inst Biomedical Res |
Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
|
|
WO2020232303A1
(en)
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
|
JP2022541125A
(ja)
|
2019-06-27 |
2022-09-22 |
サイファー メディシン コーポレーション |
患者を層別化するための分類子の開発
|
|
CA3156761A1
(en)
|
2019-10-22 |
2021-04-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
|
WO2021090062A1
(en)
*
|
2019-11-07 |
2021-05-14 |
Eisai R&D Management Co., Ltd. |
Anti-mesothelin eribulin antibody-drug conjugates and methods of use
|
|
IL295063A
(en)
|
2020-02-04 |
2022-09-01 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Chimeric antigen receptors (car) against dinitrophenol
|
|
BR112022016550A2
(pt)
|
2020-02-21 |
2022-11-16 |
Harpoon Therapeutics Inc |
Proteínas de ligação a flt3 e métodos de uso
|
|
US20240279353A1
(en)
*
|
2020-07-06 |
2024-08-22 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
CN116685604A
(zh)
*
|
2020-12-09 |
2023-09-01 |
南京再明医药有限公司 |
抗人msln的抗体及其用途
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
US20240050569A1
(en)
*
|
2020-12-18 |
2024-02-15 |
Bioardis, Llc |
Mesothelin binding molecules and uses thereof
|
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
WO2022235295A1
(en)
*
|
2021-05-07 |
2022-11-10 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
CA3216228A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
WO2023051414A1
(zh)
*
|
2021-09-30 |
2023-04-06 |
北恒医疗有限公司 |
靶向间皮素的抗体及其用途
|
|
TW202321296A
(zh)
|
2021-10-06 |
2023-06-01 |
美商鏈接免疫療法公司 |
抗間皮素抗原結合分子及其用途
|
|
WO2023064876A1
(en)
*
|
2021-10-14 |
2023-04-20 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
MX2024003887A
(es)
|
2021-10-14 |
2024-07-09 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
|
|
US20240417446A1
(en)
|
2021-10-26 |
2024-12-19 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
|
EP4448566A1
(en)
|
2021-12-17 |
2024-10-23 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
|
|
CN119874940A
(zh)
*
|
2021-12-29 |
2025-04-25 |
上海细胞治疗集团股份有限公司 |
抗间皮素纳米抗体嵌合抗原受体及其应用
|
|
EP4461747A4
(en)
*
|
2022-01-06 |
2026-04-15 |
Oricell Therapeutics Co Ltd |
ANTIGEN-BINDING PROTEIN TARGETTING MSLN AND ITS USE
|
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
CN116003638B
(zh)
*
|
2023-01-20 |
2023-09-05 |
北京基因启明生物科技有限公司 |
一种有效杀伤胆管型肝癌的CAR-iNKT细胞技术
|
|
WO2024165567A1
(en)
*
|
2023-02-06 |
2024-08-15 |
Universite D'aix-Marseille |
Anti-mesothelin nanobodies, constructs and conjugates
|
|
EP4701654A2
(en)
|
2023-04-25 |
2026-03-04 |
Arsenal Biosciences, Inc. |
Novel receptors for transcription regulation
|
|
WO2024238346A1
(en)
|
2023-05-12 |
2024-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
|
|
CN116751300A
(zh)
*
|
2023-06-15 |
2023-09-15 |
上海斯丹赛生物技术有限公司 |
抗间皮素重链单域抗体及其在癌症治疗中的应用
|
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
WO2025063790A1
(ko)
*
|
2023-09-20 |
2025-03-27 |
주식회사 유씨아이테라퓨틱스 |
항-메소텔린 항체 및 이의 용도
|
|
WO2025143287A1
(ko)
*
|
2023-12-27 |
2025-07-03 |
서울대학교산학협력단 |
메소텔린에 특이적인 항체 및 이의 용도
|
|
AU2025218272A1
(en)
|
2024-02-07 |
2026-06-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|
|
WO2026095670A1
(ko)
*
|
2024-10-30 |
2026-05-07 |
주식회사 셀렌진 |
메소텔린의 c-말단에 특이적으로 결합하는 항체 또는 이의 항원 결합 단편 및 이의 용도
|
|
WO2026152120A2
(en)
|
2025-01-13 |
2026-07-16 |
HCW Biologics, Inc. |
Chimeric polypeptides and uses thereof
|
|
WO2026165109A1
(en)
|
2025-01-28 |
2026-08-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tem8 monoclonal antibodies and their use
|